Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY) Short Interest Update

Key Points

• Short interest plunged 81.3% to 78,484 shares as of March 31 (from 419,845 on March 15), resulting in a short‑interest ratio of 0.1 days and effectively 0.0% of shares short sold.
• Daiichi Sankyo beat EPS estimates ($0.30 vs. $0.25) but missed revenue ($3.65B vs. $3.88B); the stock has a market cap of $33.28B, a P/E of 16.12, and a 52‑week range of $17.44–$28.21.

Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY - Get Free Report) saw a large decline in short interest in March. As of March 31st, there was short interest totaling 78,484 shares, a decline of 81.3% from the March 15th total of 419,845 shares. Based on an average daily trading volume, of 845,596 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the shares of the stock are short sold.

Daiichi Sankyo Price Performance

Daiichi Sankyo stock opened at $17.57 on Friday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.85 and a current ratio of 2.69. Daiichi Sankyo has a 52 week low of $17.44 and a 52 week high of $28.21. The stock has a market capitalization of $33.28 billion, a P/E ratio of 16.12, a price-to-earnings-growth ratio of 0.92 and a beta of -0.04. The stock has a fifty day moving average of $18.51 and a 200-day moving average of $21.44.

Daiichi Sankyo (OTCMKTS:DSNKY - Get Free Report) last posted its quarterly earnings results on Thursday, January 29th. The company reported $0.30 EPS for the quarter, topping analysts' consensus estimates of $0.25 by $0.05. The company had revenue of $3.65 billion during the quarter, compared to analysts' expectations of $3.88 billion. Daiichi Sankyo had a return on equity of 18.64% and a net margin of 14.83%. On average, sell-side analysts expect that Daiichi Sankyo will post 0.73 earnings per share for the current fiscal year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.